


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
VYALEV™ is a combination injectable medication consisting of foscarbidopa (an aromatic amino acid decarboxylation inhibitor) and foslevodopa (an aromatic amino acid), which is designed to provide continuous dopaminergic stimulation through subcutaneous administration. The drug is administered via a specialized infusion pump (VYAFUSER), typically in the abdominal region, allowing for precise control over the delivery of the medication. It is used to address motor fluctuations in patients with advanced Parkinson's disease who require more consistent dopaminergic therapy to manage the progressive symptoms of their condition.
VYALEV is a highly effective treatment for managing "off" episodes and motor control in Parkinson’s disease patients. It combines the benefits of foscarbidopa and foslevodopa, ensuring that levodopa is optimally available to the brain while minimizing peripheral conversion and side effects. As a subcutaneous infusion, it offers patients an alternative to oral medication regimens, ensuring more stable blood levels of levodopa, which can lead to a reduction in motor fluctuations. This method of delivery is particularly useful for those with advanced disease and significant daily motor disability.
VYALEV™ is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease. Specifically, it is used to manage "off" periods and enhance the motor control for individuals who experience inconsistent movement control as part of the disease progression.
Administration Route: Subcutaneous injection.
Preferred Injection Site: The abdomen is the recommended site for injection.
Administration Device: The VYAFUSER pump is used to administer VYALEV™.
Dosage Calculation: Dosage should be individualized for each patient. The full prescribing information provides detailed instructions on the calculation of base continuous dosage, hourly infusion rates, and adjustments such as loading doses or extra doses based on patient response.
Maximum Recommended Daily Dosage: 3,525 mg of foslevodopa (approximately equivalent to 2,500 mg levodopa) per day.
